AnaptysBio Inc (ANAB)
20.17
-0.58
(-2.80%)
USD |
NASDAQ |
Nov 14, 16:00
20.23
+0.06
(+0.30%)
After-Hours: 20:00
AnaptysBio Cash and Short Term Investments (Quarterly): 430.12M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 430.12M |
| June 30, 2024 | 350.80M |
| March 31, 2024 | 354.66M |
| December 31, 2023 | 390.90M |
| September 30, 2023 | 413.05M |
| June 30, 2023 | 429.49M |
| March 31, 2023 | 431.15M |
| December 31, 2022 | 441.24M |
| September 30, 2022 | 442.97M |
| June 30, 2022 | 442.15M |
| March 31, 2022 | 505.62M |
| December 31, 2021 | 548.10M |
| September 30, 2021 | 374.06M |
| June 30, 2021 | 390.85M |
| March 31, 2021 | 380.36M |
| December 31, 2020 | 393.65M |
| September 30, 2020 | 338.35M |
| June 30, 2020 | 377.88M |
| March 31, 2020 | 362.48M |
| December 31, 2019 | 374.23M |
| Date | Value |
|---|---|
| September 30, 2019 | 421.00M |
| June 30, 2019 | 422.22M |
| March 31, 2019 | 415.66M |
| December 31, 2018 | 427.08M |
| September 30, 2018 | 493.81M |
| June 30, 2018 | 267.91M |
| March 31, 2018 | 248.16M |
| December 31, 2017 | 248.41M |
| September 30, 2017 | 115.72M |
| June 30, 2017 | 106.36M |
| March 31, 2017 | 103.50M |
| December 31, 2016 | 51.23M |
| September 30, 2016 | 47.13M |
| June 30, 2016 | 50.59M |
| March 31, 2016 | 49.32M |
| December 31, 2015 | 51.68M |
| September 30, 2015 | 55.24M |
| June 30, 2015 | 16.89M |
| December 31, 2014 | 22.19M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
338.35M
Minimum
Sep 2020
548.10M
Maximum
Dec 2021
408.61M
Average
392.28M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Eli Lilly and Co | 3.518B |
| Regeneron Pharmaceuticals Inc | 9.796B |
| Ligand Pharmaceuticals Inc | 219.64M |
| Agios Pharmaceuticals Inc | 1.005B |
| ADMA Biologics Inc | 86.71M |